The Company held cash reserves of $0.760 million at the end of...

The Company held cash reserves of $0.760 million at the end of June, with net cash inflows fromoperating activities during the quarter of $0.284 million.Receipts from customers, at $1.903 million, was received for services under Invion’s R&D servicesagreement with The Cho Group, a Hong Kong based group that funds and has successfullycommercialised a number of unique and advanced technologies.Subsequent to the end of the quarter, in accordance with the R&D services agreement, Invion invoicedThe Cho Group in advance for activities anticipated to be undertaken in the September quarter.During the June quarter, Invion announced that its research partner, the Hudson Institute of MedicalResearch, had completed initial in vivo experiments in animal models to examine the uptake,localisation and clearance from tumour tissue of Invion’s photosensitiser, IVX-P02.